CYP2C19基因多态性与阿那曲唑治疗绝经后乳腺癌患者疗效的相关性OA北大核心CSTPCD
Association of CYP2C19 gene polymorphism with anastrozole in treatment of postmenopausal breast can-cer patients
目的 探讨绝经后乳腺癌患者CYP2C19*2基因多态性与阿那曲唑疗效的相关性.方法 采用PCR法检测绝经后乳腺癌患者和绝经后健康志愿者的基因多态性,术后给予阿那曲唑治疗.治疗后第4、12周检测FSH、LH水平、记录不良反应情况及随访5年无病生存情况.结果 A等位基因频率(OR=3.146,95% CI:1.244~7.275,P<0.05)是影响绝经后乳腺癌患者疗效的危险因素,AA和GA型的5年无病生存率低于GG型(χ2=6.26,P<…查看全部>>
Objective To investigate the correlation between CYP2C19*2 gene polymorphism and efficacy of anastrozole in postmenopausal women with breast cancer. Methods The polymorphisms of CYP2C19*2 gene in postmenopausal women with postmenopausal breast cancer were detected by PCR. Results The A allele frequency of the CYP2C19*2 gene(OR=3.146,95% CI:1.244~7.275,P<0.05)was a risk factor for the efficacy of post-menopausal breast cancer patients.The survival rate was…查看全部>>
侯倩倩;李玲玲;王大庆;杨虎;谷巍
河北省衡水市哈励逊国际和平医院肿瘤内科 河北衡水053000河北省衡水市哈励逊国际和平医院肿瘤内科 河北衡水053000河北省衡水市哈励逊国际和平医院肿瘤内科 河北衡水053000河北省衡水市哈励逊国际和平医院肿瘤内科 河北衡水053000河北省衡水市哈励逊国际和平医院肿瘤内科 河北衡水053000
绝经后乳腺癌CYP2C19*2基因多态性阿那曲唑
postmenopausal breast cancerCYP2C19*2gene polymorphismanastrozole
《实用医学杂志》 2018 (3)
460-463,4
评论